Crystalline form of the compound (s)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol
AssigneeIdorsia Pharmaceuticals Ltd
InventorsCyrille Lescop, Jasper Dingemanse, Andreas Krause
Life of this patent
Estimating the term…
Abstract
The present invention relates to a crystalline form of the compound (S)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol.
Claims26
A pharmaceutical composition comprising a crystalline form of the compound (S)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol and a pharmaceutically acceptable carrier, wherein the crystalline form is characterized by the presence of peaks in the X-ray powder diffraction diagram at the following angles of refraction 2θ:
- 5.4°, 8.5°, and 10.8°;
- and wherein the pharmaceutical composition comprises about 2 mg or about 4 mg of the compound.
A method for manufacturing a pharmaceutical composition comprising the compound (S)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol and a pharmaceutically acceptable carrier, wherein the manufacturing of the pharmaceutical composition comprises the step of admixing a crystalline form of the compound (S)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol with the pharmaceutically acceptable carrier;
- and wherein the crystalline form of the compound (S)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol is characterized by the presence of peaks in the X-ray powder diffraction diagram at the following angles of refraction 2θ:
- 5.4°, 8.5°, and 10.8°.
Dependencies are inferred from the claim text.